Therefore, future clinical trials should examine the association between IGFBP5 serum or CSF levels, structural brain magnetic resonance imaging, cognitive performance, and the incidence of dementia and AD in a large, prospective cohort of cognitively healthy adults. Here, IGFBP5 is linked to dementia.